These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Koch MW; Mostert J; Repovic P; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G J Neurol; 2022 Oct; 269(10):5319-5327. PubMed ID: 35570237 [TBL] [Abstract][Full Text] [Related]
11. Interferon Beta for primary progressive multiple sclerosis. Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E Cochrane Database Syst Rev; 2010 Jan; (1):CD006643. PubMed ID: 20091602 [TBL] [Abstract][Full Text] [Related]
12. Interferon beta for primary progressive multiple sclerosis. Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E Cochrane Database Syst Rev; 2009 Jan; (1):CD006643. PubMed ID: 19160292 [TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany. Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498 [TBL] [Abstract][Full Text] [Related]
14. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442 [TBL] [Abstract][Full Text] [Related]
16. Teriflunomide for multiple sclerosis. He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose. Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920 [TBL] [Abstract][Full Text] [Related]
18. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. Goldberg SB; Supko JG; Neal JW; Muzikansky A; Digumarthy S; Fidias P; Temel JS; Heist RS; Shaw AT; McCarthy PO; Lynch TJ; Sharma S; Settleman JE; Sequist LV J Thorac Oncol; 2012 Oct; 7(10):1602-8. PubMed ID: 22878749 [TBL] [Abstract][Full Text] [Related]
19. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital. Hosokawa Y; Oiwa H Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656 [TBL] [Abstract][Full Text] [Related]
20. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]